Compare IPST & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | LUCD |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 190.8M |
| IPO Year | N/A | 2021 |
| Metric | IPST | LUCD |
|---|---|---|
| Price | $0.38 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.20 | $4.13 |
| AVG Volume (30 Days) | ★ 3.9M | 685.1K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | $66.39 | $115.58 |
| Revenue Next Year | $60.33 | $130.54 |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $0.24 | $0.95 |
| 52 Week High | $15.08 | $1.70 |
| Indicator | IPST | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 49.98 |
| Support Level | $0.24 | $1.01 |
| Resistance Level | $0.80 | $1.52 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 29.92 | 43.74 |
Heritage Distilling Holding Co Inc is a craft distiller producing, marketing, and selling a diverse line of award-winning craft spirits, including whiskeys, vodkas, gins, rums, and ready-to-drink canned cocktails. The company sells its products through wholesale distribution, directly to consumers through its owned and operated distilleries and tasting rooms located in Washington and Oregon, and by shipping directly to consumers online, where legal. Currently, it sells products in the Pacific Northwest with limited distribution in other states throughout the U.S.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.